2012
DOI: 10.1158/1078-0432.ccr-12-1659
|View full text |Cite
|
Sign up to set email alerts
|

Biomarkers in Hepatocellular Carcinoma—Letter

Abstract: We read with great interest the study by Llovet and colleagues (1), who reported on plasma biomarkers in a phase III trial of sorafenib for advanced hepatocellular carcinoma (HCC; ref. 2). One of the main scopes of this correlative study was to identify predictive markers of survival and response to sorafenib. Within a panel of 10 candidate biomarkers that were analyzed in both the placebo and the sorafenib arm of the trial (2), the authors tested the interaction between sorafenib treatment and each biomarker … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2013
2013
2017
2017

Publication Types

Select...
3
1

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 5 publications
0
2
0
Order By: Relevance
“…Surgical resection, providing a long-term survival of HCC patients, is regarded as one of the standard treatments of HCC if the tumor is resectable (Personeni et al, 2012;Zhou et al, 2012b). However, approximately 30-50% patients develop HCC recurrence during the first year after surgery, and in general, the recurrent HCCs are more diffuse and hardly treatable Zhu et al, 2013).…”
Section: Introductionmentioning
confidence: 99%
“…Surgical resection, providing a long-term survival of HCC patients, is regarded as one of the standard treatments of HCC if the tumor is resectable (Personeni et al, 2012;Zhou et al, 2012b). However, approximately 30-50% patients develop HCC recurrence during the first year after surgery, and in general, the recurrent HCCs are more diffuse and hardly treatable Zhu et al, 2013).…”
Section: Introductionmentioning
confidence: 99%
“…The angiogenesis biomarkers, Ang2 and VEGF, were reported to be independent prognostic markers of survival. Nevertheless, when authors tested the interaction between sorafenib treatment and each biomarker level at baseline, no biomarker was found to predict the benefit deriving from sorafenib over placebo [23,24].…”
Section: Overview Of the Marketmentioning
confidence: 99%